Kim Forbes-McKean PhD, joins NDA Group from a distinguished career spanning more than 30 years of leading research and development activities for large pharma, as well as small biotech companies.
“Kim brings with her tremendous experience of the challenges facing development companies all over the world,” commented Johan Strömquist, CEO NDA Group.
“I am very happy and proud to have her join the NDA Group management team to further expand our activities in the US and I believe her expertise and experience will be of great value to our clients.”
Prior to joining NDA Kim was responsible for worldwide development of dermatology products at various companies including, Rhône-Poulenc Rorer, Aventis-Sanofi and Aqua Almirall, overseeing seven successful regulatory approvals and product launches.
She co-founded a dermatological development company and has been an executive member of management teams who have successfully raised over $90 million to support business development, licensing objectives and drug development activities which lead to partnering or acquisition opportunities.
Kim has built and led teams across all phases of development to advance global drug and device programs as well as for support and maintenance of commercial products. She has extensive experience and has served as a company representative directly interacting with the FDA throughout the development and approval process.
“In Kim, not only do we have an accomplished scientist and strategic regulatory thinker, but an experienced business professional who has been in our clients’ shoes,” commented Laurie Smaldone-Alsup, CSO/CMO NDA Group. “Kim understands the pressures and priorities of large pharma as well as small biotechs and the trade-offs facing CEOs and drug development executives on a daily basis. I am delighted to welcome her to our team. “
